Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.
Aaron E. Katz, MD, FACS
Advertisement
Articles by Aaron E. Katz, MD, FACS
Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.
Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.
Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.
Advertisement
Latest Updated Articles
Dr. Katz on Determining Low-Risk Disease in Prostate CancerPublished: June 2nd 2020 | Updated:
Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPSPublished: June 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5